Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Laekna, Inc.

Equities

2105

KYG5340S1093

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:32 2024-05-29 EDT 		5-day change 1st Jan Change
6.8 HKD -3.41% Intraday chart for Laekna, Inc. -4.49% -65.83%
05-23 US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
05-23 Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug
Lekna, Inc. Obtains IND Approval from the CDE for LAE102
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102
Laekna Shrinks Loss in Fiscal 2023
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102
Laekna, Inc. Announces Management Changes
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34%
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China
Laekna, Inc. Announces Executive Changes
Laekna, Inc. Announces Presentation of the Study Results from Core Product Furesertib at the 2023 SABCS
Laekna, Inc. Announces Resignation of Ji Dongmei as Non-Executive Director
Laekna Shrinks Loss in H1
Laekna, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Hong Kong Stocks Drop Over Weak China Data Bets; Laekna Closes 20% Higher at Debut
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2105 Stock
  4. News Laekna, Inc.
  5. Other languages